StockNews.AI
RVNC
StockNews.AI
186 days

Revance Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before March 4, 2025 to Discuss Your Rights - RVNC

1. Revance Therapeutics faces a class action lawsuit over alleged securities fraud. 2. The lawsuit claims Revance breached a Distribution Agreement with Teoxane. 3. Investors may recover losses from February to December 2024. 4. The firm represents investors at no cost for participation. 5. This case could influence RVNC's reputation and stock performance.

4m saved
Insight
Article

FAQ

Why Bearish?

Legal troubles can negatively affect investor confidence and stock price. Past examples show that lawsuits often lead to declines in stock value.

How important is it?

The lawsuit indicates potential substantial financial risk for RVNC investors, impacting stock value significantly.

Why Short Term?

Pending litigation results may immediately impact RVNC's stock. Historical trends show investor reactions to lawsuits typically affect prices quickly.

Related Companies

NEW YORK, Feb. 14, 2025

/PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ: RVNC) of a class action securities lawsuit.

CLASS DEFINITION:

The lawsuit seeks to recover losses on behalf of Revance investors who were adversely affected by alleged securities fraud between February 29, 2024 and December 6, 2024. Follow the link below to get more information and be contacted by a member of our team:

https://zlk.com/pslra-1/revance-therapeutics-inc-lawsuit-submission-form?prid=129221&wire=4

RVNC investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.

CASE DETAILS:

The filed complaint alleges that defendants made false statements and/or concealed that: (i) Revance was in material breach of the Distribution Agreement with Teoxane, which granted Revance "the exclusive right to import, market, promote, sell and distribute Teoxane's line of dermal fillers; (ii) the foregoing subjected the Company to an increased risk of litigation, as well as monetary and reputational harm; (iii) all the foregoing increased the risk that the tender offer would be delayed and/or amended; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

WHAT'S NEXT?

If you suffered a loss in Revance during the relevant time frame, you have until March 4, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

NO COST TO YOU:

If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.

WHY LEVI & KORSINSKY:

Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States.

CONTACT:

Levi & Korsinsky, LLP

Joseph E. Levi, Esq.

Ed Korsinsky, Esq.

33 Whitehall Street, 17th Floor

New York, NY 10004

Email: [email protected]

Tel: (212) 363-7500

Fax: (212) 363-7171

Website: www.zlk.com

SOURCE Levi & Korsinsky, LLP

Related News